# A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

> **NCT01031472** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 24 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** GSK2248761 formulation 1
- **DRUG:** GSK2248761 reference formulation
- **DRUG:** GSK2248761 formulation 3
- **DRUG:** GSK2248761 formulation 2 or 4

## Key facts

- **NCT ID:** NCT01031472
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-21
- **Primary completion:** 2010-03-11
- **Final completion:** 2010-03-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01031472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01031472, "A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01031472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*